Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours

NuklearMedizin

Volumn 47, Issue 6, 2008, Pages 261-265

  Elgeti, Florian ^a   Amthauer, H ^b   Denecke, T ^a   Steffen, I ^a   Heuck, F ^a   Stelter, L ^a   Ruf, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Breast cancer; Neuroendocrine tumour; PET CT; Somatostatin receptor scintigraphy

Indexed keywords

DOTATOC GA 68; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY;

EID: 57349149410     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0185     Document Type: Article

References (29)

1. Alberini JL, Meunier B, Denzler B et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 2000; 61: 21-32.
2. Cho KR, Seo BK, Lee JY et al. A comparative study of 2D and 3D ultrasonography for evaluation of solid breast masses. Eur J Radiol 2005; 54: 365-370.
3. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-147.
4. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
5. Hoyer D, Bell GI, Berelowitz M et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
6. Inoue M, Sano T, Watai R et al. Dynamic multidetector CT of breast tumors: diagnostic features and comparison with conventional techniques. AJR Am J Roentgenol 2003; 181: 679-686.
7. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170: 681-686.
8. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-48.
9. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
10. Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244: 356-378.
11. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer 2003; 97: 934-959.
12. Orlando C, Raggi CC, Bianchi S et al. Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue. Endocr Relat Cancer 2004; 11: 323-332.
13. Palmedo H, Schomburg A, Grünwald F et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
14. Plockinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
15. Prommegger R, Ensinger C, Steiner P et al. Neuroendocrine tumors and second primary malignancy - a relationship with clinical impact? Anticancer Res 2004; 24: 1049-1051.
16. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5977.
17. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
18. Reubi JC, Waser B, Foekens JA et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990; 46: 416-420.
19. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
20. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
21. RKI GdeKiDeVGu. Krebs in Deutschland. Saarbrücken 2006.
22. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43-68.
23. Sardanelli F, Calabrese M, Zandrino F et al. Dynamic helical CT of breast tumors. J Comput Assist Tomogr 1998; 22: 398-407.
24. Schima W. MRI of the pancreas: tumours and tumour-simulating processes. Cancer Imaging 2006; 6: 199-203.
25. 18F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 2007; 6: 213-220.
26. Skanberg J, Ahlman H, Benjegard SA et al. Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer. Breast Cancer Res Treat 2002; 74: 101-111.
27. Van Eijck CH, Krenning EP, Bootsma A et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640-643.
28. Wolz G, Nomayr A, Hothorn T et al. Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET. Nuklearmedizin 2007; 46: 43-48.
29. Yamamoto A, Fukushima H, Okamura R et al. Dynamic helical CT mammography of breast cancer. Radiat Med 2006; 24: 35-40.